Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/8/2025 | $7.00 → $6.00 | Outperform → Sector Perform | RBC Capital Mkts |
12/20/2024 | $5.50 | Equal-Weight | Stephens |
7/25/2024 | $18.50 | Buy | B. Riley Securities |
4/4/2024 | $15.00 | Mkt Outperform | JMP Securities |
1/3/2024 | $15.00 | Equal Weight | Barclays |
2/2/2023 | $30.00 | Buy | B. Riley Securities |
11/1/2022 | $19.00 | Buy | Stifel |
7/15/2022 | $38.00 | Outperform | SVB Leerink |
WALTHAM, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced organizational updates and leadership advancements designed to accelerate the Company's Rule of 40 strategy—balancing sustained growth with increased profitability. These changes reflect the strength of the Company's leadership bench and CEO Steve Silvestro's commitment to aligning talent and structure with OptimizeRx's long-term strategic objectives under his management. "Over the past six months, I have had the opportunity to ev
Q2 revenue of $29.2 million, increased 55% year-over-yearQ2 gross profit increased 59% year-over-year to $18.6 millionPaid down $4.5 million of principal on outstanding term loan during Q2Increased full year 2025 guidance to a revenue range between $104 million and $108 million and adjusted EBITDA range between $14.5 million and $17.5 million WALTHAM, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today reported results for the three months ended June 30, 2025. Quarterly comparisons are
Former OptimizeRX CEO Brings Extensive Digital Health and Pharmaceutical Patient Assistance Expertise to AI-Driven Healthcare Financing Company Paynela, a leading healthcare financing company revolutionizing claim processing through artificial intelligence that leverages AI advancements to process thousands of medical claims in under a minute, today announced the appointment of William Febbo to its Board of Directors, effective immediately. Febbo brings over 30 years of experience in healthcare technology, digital health innovation, and pharmaceutical patient assistance programs to the rapidly growing company. From 2016 to 2025, Febbo served as Chief Executive Officer and Director of Op
RBC Capital Mkts downgraded OptimizeRx from Outperform to Sector Perform and set a new price target of $6.00 from $7.00 previously
Stephens initiated coverage of OptimizeRx with a rating of Equal-Weight and set a new price target of $5.50
B. Riley Securities resumed coverage of OptimizeRx with a rating of Buy and set a new price target of $18.50
8-K - OptimizeRx Corp (0001448431) (Filer)
8-K - OptimizeRx Corp (0001448431) (Filer)
4 - OptimizeRx Corp (0001448431) (Issuer)
4 - OptimizeRx Corp (0001448431) (Issuer)
4 - OptimizeRx Corp (0001448431) (Issuer)
4 - OptimizeRx Corp (0001448431) (Issuer)
4 - OptimizeRx Corp (0001448431) (Issuer)
Q2 revenue of $29.2 million, increased 55% year-over-yearQ2 gross profit increased 59% year-over-year to $18.6 millionPaid down $4.5 million of principal on outstanding term loan during Q2Increased full year 2025 guidance to a revenue range between $104 million and $108 million and adjusted EBITDA range between $14.5 million and $17.5 million WALTHAM, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today reported results for the three months ended June 30, 2025. Quarterly comparisons are
WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, August 7, 2025, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Thursday, August 7, 2025Time:4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)T
Q1 revenue of $21.9 million, increasing 11% year-over-yearQ1 gross profit increased 9% year-over-year to $13.3 millionIncreases full year 2025 guidance to a revenue range between $101 million and $106 million and adjusted EBITDA range between $13 million and $15 million WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today reported results for the three months ended March 31, 2025. Quarterly comparisons are to the same year-ago period. Financial Highlights Revenue in the first quarter of 2025
WALTHAM, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced organizational updates and leadership advancements designed to accelerate the Company's Rule of 40 strategy—balancing sustained growth with increased profitability. These changes reflect the strength of the Company's leadership bench and CEO Steve Silvestro's commitment to aligning talent and structure with OptimizeRx's long-term strategic objectives under his management. "Over the past six months, I have had the opportunity to ev
Former OptimizeRX CEO Brings Extensive Digital Health and Pharmaceutical Patient Assistance Expertise to AI-Driven Healthcare Financing Company Paynela, a leading healthcare financing company revolutionizing claim processing through artificial intelligence that leverages AI advancements to process thousands of medical claims in under a minute, today announced the appointment of William Febbo to its Board of Directors, effective immediately. Febbo brings over 30 years of experience in healthcare technology, digital health innovation, and pharmaceutical patient assistance programs to the rapidly growing company. From 2016 to 2025, Febbo served as Chief Executive Officer and Director of Op
WALTHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Steve Silvestro, currently serving as the Company's Chief Executive Officer, to its Board of Directors, effective as of June 20, 2025. Mr. Silvestro joined the Company in 2019 and has been the Company's CEO since March 2025, after serving as the interim CEO from January 2025. The appointment of Mr. Silvestro, with his knowledge of the Company and expertise in the industry, will enhance overall leadership and gre
SC 13G/A - OptimizeRx Corp (0001448431) (Subject)
SC 13G - OptimizeRx Corp (0001448431) (Subject)
SC 13G/A - OptimizeRx Corp (0001448431) (Subject)